Ekaterina V. Parkhomenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ekaterina V. Parkhomenko has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aleksey N. Barinov
Neurology and Psychotherapy of Medical Academy MEDSI group, 123056 Moscow, Russia
2 shared publications - E. V. Emikh
Group of companies ‘MEDSI
2 shared publications - Sergey E. Nartov
Karpov’s Neuroclinic Co
2 shared publications - Aleksandr E. Barulin
Volgograd State Medical University
1 shared publication - Assiya Khalimova
Prima Medical Group, 111024 Moscow, Russia
1 shared publication - Denis Yu. Karpov
Regional state budget health institution City Hospital No. 5
1 shared publication
Latest Publications
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- 20 March 2026
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 24 (1) , 22-30
Influence of central sensitivity syndrome on symptoms of chronic nonspecific low back pain in patients with spinal osteoarthritis
Objective. To evaluate the influence of central sensitivity syndrome (CSS) on symptoms of chronic nonspecific low back pain (LBP) in patients with spinal osteoarthritis. Material and methods. Patients with chronic nonspecific LBP (n=120) and spinal osteoarthritis (OA) were divided into two equal groups (n=60). The 1st group included patients with clinically insignificant CSS (CSI score <35). The 2nd group included patients with clinically significant CSS (CSI score ≥35). Both groups were compared regarding duration of disease and exacerbation; LBP intensity; degree of disability; risk of LBP chronicity; number of descriptors of various painful sensations and associated affective reactions. Results. Both groups were comparable regarding anthropometric parameters; duration of disease and exacerbation; back and leg pain intensity. The following parameters (median) were lower in the 1st group: total CSI score (22 vs 47 points); disability according to the Roland-Morris Disability Questionnaire (10 vs 13.5 points); risk of chronicity according to the Keele STarT Back Tool (4 vs 7 points); SF-MPQ-2 total score (41 vs 67 points). Patients in the 2nd group often complained on symptoms typical for chronic fatigue syndrome, fibromyalgia, and clinical depression. Conclusion. Central sensitivity syndrome limits daily activities of patients with chronic low back pain and exacerbates its course. Patients with chronic low back pain and clinically significant central sensitivity syndrome predominantly demonstrate symptoms typical for chronic fatigue syndrome, fibromyalgia, and depression. In such cases, low back pain may be one of the symptoms of these conditions.
- Open Access
- 23 March 2023
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 12-18
Contemporary approaches to diagnostics and treatment of nociceptive primary musculoskeletal pain
This article discusses contemporary approaches to multimodal, NSAID-sparing management of primary musculoskeletal pain. Despite the scientific advances, musculoskeletal pain remains extremely challenging to manage clinically. While the number of potential treatment targets has grown substantially and a strong case has been made for a mechanism-based and individualized approach to pain therapy, arguably clinicians are not much more advanced now in their capacity to either diagnose or effectively treat patients with musculoskeletal pain. The International Association for the Study of Pain (IASP) pain taxonomy includes pain mechanisms as one of the 3 dimensions that need to be considered when making a diagnostic classification for the concurrent use of separate therapeutic interventions with various mechanisms of action aimed at different pain mechanisms. Combination of shock-wave therapy with topical NSAID tenoxicam is more effective in primary musculoskeletal pain treatment.
- 23 March 2023
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 12-18
Open AccessContemporary approaches to diagnostics and treatment of nociceptive primary musculoskeletal pain
This article discusses contemporary approaches to multimodal, NSAID-sparing management of primary musculoskeletal pain. Despite the scientific advances, musculoskeletal pain remains extremely challenging to manage clinically. While the number of potential treatment targets has grown substantially and a strong case has been made for a mechanism-based and individualized approach to pain therapy, arguably clinicians are not much more advanced now in their capacity to either diagnose or effectively treat patients with musculoskeletal pain. The International Association for the Study of Pain (IASP) pain taxonomy includes pain mechanisms as one of the 3 dimensions that need to be considered when making a diagnostic classification for the concurrent use of separate therapeutic interventions with various mechanisms of action aimed at different pain mechanisms. Combination of shock-wave therapy with topical NSAID tenoxicam is more effective in primary musculoskeletal pain treatment.
- Open Access
- 15 April 2022
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 13 (1) , 30-41
Toxic desomorphine encephalopathy due to the use of “Krokodil”: clinical and neuroimaging features
Background: Toxic desomorphine encephalopathy (TDE) is a pathological condition that develops as a result of the intravenous use of a drug called Krokodil containing desomorphine, made in the artisanal conditions using codeine-containing drugs, organic solvents (gasoline), iodine and red phosphorus. This disease is more often observed in the CIS countries. In addition to the acute and chronic pathological conditions with the damage to various organs, the use of Krokodil is characterized by pronounced extrapyramidal manifestations in the form of dystonia, parkinsonism, postural disorders, as well as the occurrence of cognitive and affective disorders. Aims: To find the clinical and neuroimaging features of toxic desomorphine encephalopathy, as well as possible methods of its treatment. Methods: A clinical analysis of the medical documentation of 21 TDE patients (11 women and 10 men) with a history of the use of Krokodil was carried out, the patients had been under observation from 2014 to 2021. All the patients underwent a clinical physical and neurological examination, 14 of them underwent neuroimaging (brain MRI and/or MSCT). The observation of these patients revealed a number of characteristic clinical and neuroimaging features inherent in the majority of drug addicts. Results: The clinical picture of patients with TDE was dominated by movement disorders. All the patients had pronounced postural disorders and gait disturbance. Parkinsonism was observed in 20 of 21 patients. The hyperkinetic syndrome was presented in 17 patients (80.9%) and was manifested by dystonia of various localization with polymorphic manifestations. The brain MRI data taken from the Krokodil users for 3 years were characterized by symmetrical focal changes in the basal ganglia, brainstem, cerebellum and internal capsule of the thalamus in the form of an increase in the intensity of the MR signal in the T1 mode and attenuation in the T2-weighted images mode (7 of 11 cases), with the subsequent regression of these characteristics based on the results of the subsequent MRI studies. Conclusion: The study results have revealed the clinical manifestations characteristic of TDE polymorphic extrapyramidal disorders, as well as neuroimaging changes reflecting these data.
- 15 April 2022
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 13 (1) , 30-41
Open AccessToxic desomorphine encephalopathy due to the use of “Krokodil”: clinical and neuroimaging features
Background: Toxic desomorphine encephalopathy (TDE) is a pathological condition that develops as a result of the intravenous use of a drug called Krokodil containing desomorphine, made in the artisanal conditions using codeine-containing drugs, organic solvents (gasoline), iodine and red phosphorus. This disease is more often observed in the CIS countries. In addition to the acute and chronic pathological conditions with the damage to various organs, the use of Krokodil is characterized by pronounced extrapyramidal manifestations in the form of dystonia, parkinsonism, postural disorders, as well as the occurrence of cognitive and affective disorders. Aims: To find the clinical and neuroimaging features of toxic desomorphine encephalopathy, as well as possible methods of its treatment. Methods: A clinical analysis of the medical documentation of 21 TDE patients (11 women and 10 men) with a history of the use of Krokodil was carried out, the patients had been under observation from 2014 to 2021. All the patients underwent a clinical physical and neurological examination, 14 of them underwent neuroimaging (brain MRI and/or MSCT). The observation of these patients revealed a number of characteristic clinical and neuroimaging features inherent in the majority of drug addicts. Results: The clinical picture of patients with TDE was dominated by movement disorders. All the patients had pronounced postural disorders and gait disturbance. Parkinsonism was observed in 20 of 21 patients. The hyperkinetic syndrome was presented in 17 patients (80.9%) and was manifested by dystonia of various localization with polymorphic manifestations. The brain MRI data taken from the Krokodil users for 3 years were characterized by symmetrical focal changes in the basal ganglia, brainstem, cerebellum and internal capsule of the thalamus in the form of an increase in the intensity of the MR signal in the T1 mode and attenuation in the T2-weighted images mode (7 of 11 cases), with the subsequent regression of these characteristics based on the results of the subsequent MRI studies. Conclusion: The study results have revealed the clinical manifestations characteristic of TDE polymorphic extrapyramidal disorders, as well as neuroimaging changes reflecting these data.
- 1 January 2022
- Published by Altay State Medical University in Bulletin of Medical Science
- No. 4,p. 128-132
ARTERIAL HYPERTENSION AND MIGRAINE: CURRENT STATUS OF THE PROBLEM
- 1 January 2022
- Published by Altay State Medical University in Bulletin of Medical Science
- No. 4,p. 128-132
ARTERIAL HYPERTENSION AND MIGRAINE: CURRENT STATUS OF THE PROBLEM
- 28 March 2021
- Published by Alfmed LLC in Medical alphabet
- No. 3,p. 14-22
Clinical features, pathogenesis and treatment of long-haul COVID‑19 impact on nervous system
The current outbreak of coronavirus SARS-CoV‑2 (COVID-19) has raised great concern worldwide, but its impact on nervous system still needs more investigation. Thirty per cent of symptomatic patients with COVID‑19 will have symptoms that last longer than the typical two weeks, 10 % have symptoms longer than 3 months and this is called ‘long-COVID’. These symptoms affect not only people with severe disease, but also those with milder cases. Many long-haulers experience the same symptoms they had during their initial fight with COVID‑19, such as fatigue, cognitive impairment (or brain fog), difficulty breathing, headache, depression, insomnia and loss of the sense of taste and\or smell. Treatment of those complications with citicoline, ethylmethylhydroxypyridine succinate and vitamin B improves these symptoms in patients but most of them also need cognitive therapy for dehypochondrisation.
- 28 March 2021
- Published by Alfmed LLC in Medical alphabet
- No. 3,p. 14-22
Clinical features, pathogenesis and treatment of long-haul COVID‑19 impact on nervous system
The current outbreak of coronavirus SARS-CoV‑2 (COVID-19) has raised great concern worldwide, but its impact on nervous system still needs more investigation. Thirty per cent of symptomatic patients with COVID‑19 will have symptoms that last longer than the typical two weeks, 10 % have symptoms longer than 3 months and this is called ‘long-COVID’. These symptoms affect not only people with severe disease, but also those with milder cases. Many long-haulers experience the same symptoms they had during their initial fight with COVID‑19, such as fatigue, cognitive impairment (or brain fog), difficulty breathing, headache, depression, insomnia and loss of the sense of taste and\or smell. Treatment of those complications with citicoline, ethylmethylhydroxypyridine succinate and vitamin B improves these symptoms in patients but most of them also need cognitive therapy for dehypochondrisation.
- Open Access
- 17 August 2019
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 10 (2)
Differential diagnosis short-lasting unilateral neuralgiform headache attacks and trigeminal neuralgia
The article presents diagnostic criteria, comparative characteristics of short-lasting unilateral neuralgiform headache attacks, including short-term unilateral neuralgic headaches with conjunctival injection and lacrimation (SUNCT) and short-term unilateral neuralgic headaches with cranial autonomic symptoms (SUNA), differential diagnosis with trigeminal neuralgia.
- 17 August 2019
- Published by ECO-Vector LLC in Journal of Clinical Practice
- Vol. 10 (2)
Open AccessDifferential diagnosis short-lasting unilateral neuralgiform headache attacks and trigeminal neuralgia
The article presents diagnostic criteria, comparative characteristics of short-lasting unilateral neuralgiform headache attacks, including short-term unilateral neuralgic headaches with conjunctival injection and lacrimation (SUNCT) and short-term unilateral neuralgic headaches with cranial autonomic symptoms (SUNA), differential diagnosis with trigeminal neuralgia.